Verified Market Research®’s Post

🌿 Pioneering Innovation in Vaccine Adjuvants 🌿   The recent COVID-19 pandemic demonstrated the value of vaccines as one of the most successful medical advancements in reducing diseases caused by infectious agents. The development of new vaccines highlights the need for novel and more effective immunological adjuvants.   The use of adjuvants has been crucial for the development of vaccines for specific groups and diseases for which traditional vaccines are not very effective. These substances, which enhance and modulate the immune response to vaccine antigens, are the key to the full potential of vaccination strategies. In this context, Quillaja saponins stand out as essential adjuvants due to their unique ability to induce both cellular and humoral immune responses. Currently, saponins produced by Desert King are components of vaccines against COVID-19 caused by the SARS-CoV-2 virus, as well as vaccines for Shingles, Malaria, and Respiratory Syncytial Virus (RSV). Desert King, with over 40 years of experience in saponin-based products, presents its commitment to innovation and the development of new immunological adjuvants based on quillaja saponins, recognizing that this is key to the sustainable development of adjuvants for the global pharmaceutical industry.   🔗 Explore More: https://shorturl.at/mwxMX 🌐 Follow Us: Stay updated on our journey by following our LinkedIn page.   #Innovation #Vaccines #GlobalHealth #Sustainability #DesertKing #Quillaja

📰 "DECIPHERING IMMUNE RESPONSES: A COMPARATIVE ANALYSIS OF INFLUENZA VACCINATION PLATFORMS." This is such a detailed and well referenced paper on immune responses to flu vaccines. The key highlights for me are: ⭐"A weak cellular immune response has been identified as a shortcoming of existing vaccines." ⭐"RNA vaccines may offer a more balanced protective immune response to flu." ImmunoServ's Immuno-T test kit makes measuring cellular immune responses to flu vaccines scalable and standardisable. This will be vital as new vaccine platforms targeting T cells are developed.

Vaccines play a crucial role in preventing infectious diseases, with various types each carrying their own set of advantages and disadvantages. Understanding these distinctions is key to enhancing accessibility. Here's a breakdown of different vaccine types and how Unity Health Pharmaceutical's approach can contribute to broader availability: - Live Attenuated Vaccines: Offer strong and lasting immune responses, though challenging for individuals with weakened immune systems. Unity Health could focus on improving cold chain logistics or developing stable formulations to extend shelf life in remote areas. - Inactivated (Killed) Vaccines: Safe for weakened immune systems but may need multiple doses for full immunity. Unity Health can innovate by creating combined vaccines to reduce doses required, enhancing adherence and cutting vaccination costs. - Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines: Deliver targeted immune responses but may need booster shots. Unity Health could invest in technology to streamline production, making these vaccines more affordable and scalable, especially in low-income regions. - mRNA Vaccines: Known for rapid development and efficacy but require ultra-cold storage. Unity Health's focus on stable mRNA vaccines at higher temperatures can ease cold chain requirements, enhancing accessibility in remote areas. - Viral Vector Vaccines: Offer strong immune responses with fewer doses but may face challenges with pre-existing immunity and rare side effects. Unity Health's strategies could target affordability, distribution, education, and technology to enhance accessibility. By understanding the nuances of vaccine types and tailoring accessibility strategies, Unity Health Pharmaceutical aims to advance global health outcomes. #Vaccines #PublicHealth #UnityHealthPharma

Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines. More information Liu, F., Gross, F.L., Joshi, S. et al. Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines. Nat Commun 15, 254 (2024). https://lnkd.in/gH__Attx

Vaccines are estimated to save over 4 million lives annually, making them a cornerstone of public health, especially in low- and middle-income countries (LMICs). They not only protect us from infections but also play a crucial role in reducing the need for antibiotics, thus addressing antimicrobial resistance #AMR. The exact impact of #vaccines on AMR and their economic benefits need further exploration. 📢That is why the International Vaccine Institute (IVI) is excited to partner with The International Centre for Antimicrobial Resistance Solutions (ICARS)  to announce a joint Request for Proposal (RFP). We invite proposals from South and South-East Asian LMICs to develop strategies that highlight AMR as a key metric in vaccine investment cases. With a population of 2.4 billion in South Asia and 675 million in South-East Asia, the region faces a high burden of AMR. Robust immunization programs and a network of partners in vaccine research and development make these areas ideal for impactful projects. 🤝 Join us in creating a knowledge network of vaccine and AMR stakeholders to lead the charge in using vaccines to manage AMR! 🔗 Learn more and apply now: https://lnkd.in/e85_qcbw

This week's digest includes an article that calls for simplification of path to develop high-value combination vaccines. Vaccine innovation and development have historically taken a monopathogen approach, with the success of combination vaccines only evident after creating separate vaccine formulations. Despite this, multipathogen combination vaccines have emerged as an affordable, efficient way to increase adherence to routine immunization schedules and impact on health. For example, vaccines targeting multiple pathogens underlying a single clinical presentation, such as pediatric diarrhea, could have greater impacts on health than one or two standalone vaccines. Scientists call for adapting regulatory, policy, and financing strategies that recognize the value of and support the innovation of combination vaccines. Read the article published in The Lancet Global Health here: https://ow.ly/6hOm50RvljW More digest here: https://ow.ly/ZvSG50RvljT #CombinationVaccines #MultiPathogen #Immunization

Great news "Over a 3-year enrollment period, 16,235 participants received either Butantan-DV (10,259 participants) or placebo (5976 participants). The overall 2-year vaccine efficacy was 79.6% (95% confidence interval [CI], 70.0 to 86.3) — 73.6% (95% CI, 57.6 to 83.7) among participants with no evidence of previous dengue exposure and 89.2% (95% CI, 77.6 to 95.6) among those with a history of exposure." #Dengue #Vaccine #Immunology https://lnkd.in/dfjixEGA

📰 Exciting news in the fight against infectious diseases! 💉 🚀 Breakthrough in Vaccine Technology: Combined COVID-Flu Vaccine! Moderna's new combined COVID-19 and influenza vaccine has passed phase-III clinical trials, showing better protection than single-target shots. This mRNA-based vaccine promises a more efficient immunization process. 🌟Key Highlights: 🔬 Enhanced Protection: Superior immunity for adults over 50. 🧪 mRNA Technology: Combines antigens without losing effectiveness. ⏱️ Rapid Development: Quick updates for evolving virus variants. 💼 FDA Approval: Seeking approval soon. Benefits: - Increased Vaccination Rates: One shot for both viruses. - Public Health Impact: Easier access and fewer pharmacy visits. - Future Applications: Potential to add RSV and other pathogens. The University of Cambridge calls it a testament to RNA technology’s potential, and University of Pennsylvania sees it as the beginning of mRNA’s impact on immunization. Read more: Nature Portfolio https://lnkd.in/db7mAAi2 #HealthcareInnovation #mRNA #VaccineDevelopment #PublicHealth #Moderna #COVID19 #Influenza #Biotechnology #MedicalResearch

Accelerating Vaccine Development for Global Health Impact - a WHO Initiative to Prioritize Key Endemic Pathogens In a significant stride towards facilitating and informing priorities in global vaccine development for endemic pathogens, the World Health Organization (WHO) has commissioned 16 "Vaccine Value Profiles" (VVPs) to be published in a groundbreaking Supplement in the journal Vaccine. This milestone is the result of collaborations with several pathogen and vaccine experts, led by the Product Development and Research (PDR) team in WHO's Immunization, Vaccines & Biologicals department, with the primary objective of advancing the development of vaccines for pathogens that pose a substantial public health and socio-economic burden, especially in low- and middle-income countries (LMICs). #VaccineDevelopment #GlobalHealth #WHOInitiative #HealthImpact #EndemicPathogens #VaccinePrioritization #PublicHealth #InfectiousDisease #HealthSecurity #GlobalVaccination #HealthInnovation #DiseasePrevention #GlobalInitiative #HealthPriorities #VaccineResearch #GlobalHealthImpact #DiseaseControl #HealthPrioritization #WHOAction #VaccineEquity #HealthcareAdvancement https://lnkd.in/gSZxuMjE